WuXi Biologics adopt Purolite Life Sciences Protein A resin for monoclonal antibody therapies

Food and Healthcare Press Releases Thursday November 5, 2020 11:05
CARDIFF South Wales--5 Nov--PRNewswire/InfoQuest

Purolite Ltd., a global manufacturer of resin-based separation, purification and extraction technologies, today announces that it will supply its Protein A capture resin, Praesto(R) Jetted A50 to WuXi Biologics for immediate use. WuXi Biologics, a global company with leading open-access biologics technology, will utilize Praesto(R) Jetted A50 to provide their customers with additional choices for affinity chromatography resins for a range of downstream processes for monoclonal antibody purification.

Chris Major, Sales and Marketing Director for Purolite Life Sciences stated, "This is a major step forward for both Purolite Life Sciences and the wider biopharmaceutical industry, and we're extremely proud that WuXi Biologics customers will now have the option of selecting a uniform particle size, Protein A agarose resin. The adoption of Praesto(R) Jetted A50 by such a prominent organization is testament to both the commitment and expertise of Purolite's R&D team, as well as the best-in-class performance characteristics of the resin itself."

The Praesto(R) line of agarose-based chromatography resins are currently utilized in over 200 screening projects and ongoing clinical trials globally. Praesto(R) Jetted A50, is an integral technology, used by biopharmaceutical developers around the globe for the purification of modern medicines to treat ailments such as cancer, rheumatoid arthritis, dementia, and diabetes. Developed to offer leading performance combined with responsible pricing when compared to other market-leading alternatives, Praesto(R) Jetted A50 has garnered accolades across the wider biopharmaceutical industry, leading to its early adoption and implementation into several large-scale processes.

As part of the supply agreement, Purolite will supply significant volumes of Praesto(R) Jetted A50 from its cutting-edge, ISO-certified production facility in Llantrisant, South Wales, United Kingdom. One of the largest of its kind in the world, the facility is capable of satisfying as much as one-third of all global demand for these bioprocessing resins.

Logo - https://mma.prnewswire.com/media/753768/Purolite_Life_Sciences_Logo.jpg

Latest Press Release

PEOPLE LIVING WITH HIV AND INDIVIDUALS AT-RISK EXPERIENCED DISRUPTION TO HIV CARE IN THAILAND: SURVEY

Results are part of the first Asia Pacific-wide survey that assesses the impact of COVID-19 pandemic on access and delivery of HIV care in the region The survey provides insights on the adoption of telemedicine as the future of HIV care The COVID-19...

Ministry of Public Health and Department of Health Service Support leverage leading technologies to expand Alternative State Quarantine (ASQ)

Ministry of Public Health (MOPH) and Department of Health Service Support (HSS) today announced they will leverage Agoda's cutting edge digital technologies to further improve accessibility and efficiency for the booking processes of Alternative States...

European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC)...

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

MedAlliance has announced completion of patient enrolment in the ISABELLA Clinical Trial with SELUTION SLR(TM) 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis....

INSIGHTEC Announces MR-guided Focused Ultrasound to Treat Essential Tremor Received Funding by National Health Service (NHS) England

INSIGHTEC(R), a global healthcare company focused on the therapeutic power of acoustic energy, today announced that the National Health Service (NHS) England has approved funding for MR-guided Focused Ultrasound for the treatment of medication-refractory...

Related Topics